Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Huys

Showing results (31-40 of 206) with videos related to

Pageof 21
Sort By:
BMC Medical Ethics|March 2, 2016
Qualitative study on custodianship of human biological material and data stored in biobanksMichiel Verlinden, Herman Nys, Nadine Ectors, et al.
Frontiers in Pharmacology|May 10, 2021
Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic ReviewKhadidja Abdallah, Isabelle Huys, Kathleen Claes, et al.
Frontiers in Pharmacology|May 31, 2021
How to Value Orphan Drugs? A Review of European Value Assessment FrameworksAlessandra Blonda, Yvonne Denier, Isabelle Huys, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 4, 2019
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!Binita Dutta, Isabelle Huys, Arnold G Vulto, et al.
Frontiers in Pharmacology|September 8, 2017
Time Investment in Drug Supply Problems by Flemish Community PharmaciesElfi De Weerdt, Steven Simoens, Minne Casteels, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 16, 2020
European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical PracticeLiese Barbier, Steven Simoens, Arnold G Vulto, et al.
BMC Medical Ethics|August 1, 2021
Personalized and long-term electronic informed consent in clinical research: stakeholder viewsEvelien De Sutter, Pascal Borry, David Geerts, et al.
Nature Biotechnology|October 10, 2009
Legal uncertainty in the area of genetic diagnostic testingIsabelle Huys, Nele Berthels, Gert Matthijs, et al.
Acta Ophthalmologica|April 30, 2026
Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time-series analysisElif Car, Isabelle Huys, Steven Simoens, et al.
Trials|July 10, 2026
Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trialsMargaux Reckelbus, Eva Van Steijvoort, Isabelle Huys, et al.
Pageof 21

Showing results (31-40 of 206) with videos related to

Sort By:
Pageof 21
BMC Medical Ethics|March 2, 2016
Qualitative study on custodianship of human biological material and data stored in biobanksMichiel Verlinden, Herman Nys, Nadine Ectors, et al.
Frontiers in Pharmacology|May 10, 2021
Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic ReviewKhadidja Abdallah, Isabelle Huys, Kathleen Claes, et al.
Frontiers in Pharmacology|May 31, 2021
How to Value Orphan Drugs? A Review of European Value Assessment FrameworksAlessandra Blonda, Yvonne Denier, Isabelle Huys, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 4, 2019
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!Binita Dutta, Isabelle Huys, Arnold G Vulto, et al.
Frontiers in Pharmacology|September 8, 2017
Time Investment in Drug Supply Problems by Flemish Community PharmaciesElfi De Weerdt, Steven Simoens, Minne Casteels, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 16, 2020
European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical PracticeLiese Barbier, Steven Simoens, Arnold G Vulto, et al.
BMC Medical Ethics|August 1, 2021
Personalized and long-term electronic informed consent in clinical research: stakeholder viewsEvelien De Sutter, Pascal Borry, David Geerts, et al.
Nature Biotechnology|October 10, 2009
Legal uncertainty in the area of genetic diagnostic testingIsabelle Huys, Nele Berthels, Gert Matthijs, et al.
Acta Ophthalmologica|April 30, 2026
Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time-series analysisElif Car, Isabelle Huys, Steven Simoens, et al.
Trials|July 10, 2026
Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trialsMargaux Reckelbus, Eva Van Steijvoort, Isabelle Huys, et al.
Pageof 21